EP300 and posterior cortical atrophy: Since NEO2734, a novel BET and CBP/p300 dual inhibitor, offers a unique opportunity to explore the potential inhibition of both BET and CBP/p300 pathways with a single agent (Giles et al, 2018), we explored its activity in Q165P mutant PCa cells.